Erythropoietin in the critically ill: What is the evidence?

Nephrology Dialysis Transplantation

Volumn 20, Issue 12, 2005, Pages 2605-2608

  Corwin, Howard L ^a   Eckardt, Kai Uwe ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Anemia; Blood; Critical; Erythropoietin; Illness; Intensive care

Indexed keywords

HEMOGLOBIN; IMMUNOSUPPRESSIVE AGENT; IRON; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION REACTION; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; CRITICAL ILLNESS; EDITORIAL; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANEMIA; CRITICAL ILLNESS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY FAILURE, CHRONIC; TREATMENT OUTCOME;

EID: 27944450428     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfh970     Document Type: Editorial

References (33)

1. Spence RK, Cernaianu AC, Carson J, DelRossi AJ. Transfusion and surgery. Curr Probl Surg 1993; 30: 1101-1180
2. Littenberg B, Corwin H, Gettinger A, Leichter J, Aubuchon J. A practice guideline and decision aid for blood transfusion. Immunohematology 1995; 11: 88-94
3. Corwin HL, Parsonnet KC, Gettinger A. RBC transfusion in the ICU. Is there a reason? Chest 1995; 108: 767-771
4. Groeger JS, Guntupalli KK, Strosberg M et al. Descriptive analysis of critical care units in the United States: Patient characteristics and intensive care unit utilization. Crit Care Med 1993; 21: 279-291
5. Von Ahsen N, Müller C, Serke S, Frei U, Eckardt K-U. Important role of non-diagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med 1999; 27: 2630-2639
6. Vincent JL, Baron JF, Reinhart K et al. Anemia and blood transfusion in critically ill patients. JAMA 2002; 288: 1499-1507
7. Corwin HL, Gettinger A, Pearl RG et al. The CRIT Study: Anemia and blood transfusion in the critically ill: Current clinical practice in the United States. Crit Care Med 2004; 32: 39-52
8. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts - blood transfusion. N Engl J Med 1999; 340: 438-447
9. Blumberg N, Heal JM. Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med 1994; 118: 371-379
10. Landers DF, Hill GE, Wong KC, Fox IJ. Blood transfusion-induced immunomodulation. Anesth Analg 1996; 82: 187-204
11. Mickler TA, Longnecker DE. The immunosuppressive aspects of blood transfusion. J Intensive Care Med 1992; 7: 176-188
12. Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993; 269: 3024-3029
13. Fitzgerald RD, Martin CM, Dietz GE, Doig GS, Potter RF, Sibbald WJ. Transfusing red blood cells stored in citrate phosphate dextrose adenine-1 for 28 days fails to improve tissue oxygenation in rats. Crit Care Med 1997; 25: 726-732
14. Hebert PC, Wells G, Blajchman MA et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409-417
15. Corwin HL, Krantz SB. Anemia of the critically ill: 'acute' anemia of chronic disease. Crit Care Med 2000; 28: 3098-3099
16. Rodriguez RM, Corwin HL, Gettinger A, Corwin MJ, Gubler D, Pearl RG. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 2001; 16: 36-41
17. Rogiers P, Zhang H, Leeman M et al. Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997; 23: 159-162
18. Krafte-Jacobs B, Levetown ML, Bray GL, Ruttimann UE, Pollack MM. Erythropoietin response to critical illness. Crit Care Med 1994; 22: 821-826
19. Frede S, Fandrey J, Pagel H, Hellwig T, Jelkmann W. Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1 β injections in rats. Am J Physiol 1997; 273: R1067-R1071
20. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998; 18: 555-559
21. Gabriel A, Kozek S, Chiari A et al. High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfuction syndrome. J Trauma 1998; 44: 361-337
22. Corwin HL, Gettinger A, Rodriguez RM et al. Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double blind, placebo-controlled trial. Crit Care Med 1999; 27: 2346-2350
23. Corwin HL, Gettinger A, Pearl RG et al. Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized controlled trial. JAMA 2002; 288: 2827-2835
24. Silver M, Bazan A, Corwin HL, Gettinger A, Enny C, Corwin MJ. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin in long-term acute care patients. Crit Care Med 2003; 31 [Suppl]: A153
25. Goldberg MA, McCutchen JW, Jove M et al. A safety and efficacy comparison study of two dosing regimens of epoetin alpha in patients undergoing major orthopedic surgery. Am J Orthop 1996; 25: 544-552
26. Chun TY, Martin S, Lepor H. Preoperative recombinant human erythropoietin injection versus preoperative autologous blood donation in patients undergoing radical retropubic prostatectomy. Urology 1997; 50: 727-732
27. Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 2003; 18: 865-869
28. Ehrenreich H, Hasselblatt M, Dembowski CH et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8: 495-505
29. Parsa CJ, Matsumoto A, Kim J et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112: 999-1007
30. Yang CW, Li C, Jung JY et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 2003; 17: 1754-1755
31. Coleman T, Brines M. Science Review: Recombinant human erythropoietin in critical illness: A role beyond anemia. Crit Care 2004: 8: 337-341
32. Shermock KM, Horn E, Lipsett PA, Pronovost PJ, Dorman T. Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients. Crit Care Med 2005; 33: 497-503
33. Corwin HL, Hebert P. Avoiding a blood transfusion: How much is it worth? Crit Care Med 2005; 33: 672-674